Financial Market Data powered by FinancialContent Services, Inc. All rights reserved. Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.Copyright ©2015 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.
View original post here:
4 (More) Biotech Stocks to Buy | InvestorPlace
[…]
OK, listen up – it’s time to “buy the dip.”I’m talking about the biotech dip that just happened. Here’s the deal:A leading biotech company just issued some news that spooked some jittery investors. The stock took a dive, taking the entire sector down a peg or two.But this is just a temporary blip, and it’s handing you a golden chance […]
Biotech is big, and the industry has been big for quite some time.As a matter of fact, biotechnology has been the second-best performing industry over the last two years.Biotech stocks obviously come in all different shapes and sizes. Some investors like the small-caps, others prefer the middle of the road mid-caps.However, at the end of the day, the big biotechs […]
NPS CEO: Shire has rare-disease experience
NPS Pharmaceuticals president and CEO Dr. Francois Nader discusses opportunities the potential deal with Shire presents.
Anyone who follows Jim Cramer’s stock picks knows that he loves the biotech sector. Especially NPS Pharmaceuticals, up 45 percent in the past month. Wowzer!On Sunday, Ireland-based Shire PLC agreed to acquire NPS Pharma for an all cash deal of […]
The biotech sector has started 2015 with the announcement of several deals. Both Kite Pharma (KITE – Snapshot Report) and Isis Pharmaceuticals (ISIS – Analyst Report) saw their share prices increasing on collaboration agreements with major companies. Meanwhile, Alkermes (ALKS – Analyst Report) has also started the year on a positive note with encouraging pipeline data.Recap of the Week’s Most […]
SummaryBiotech stocks should outperform the market in 2015. However the biotech sector is linked to healthcare fundamentals like government pricing policy.
The industry is better financed than any time in its history driving innovation and new product growth. The appetite for M&A and IPOs will continue.
Biopharmaceutical stocks defy traditional analysis and have been a safe haven from global economic news.
2015: Another […]
“Out with the old and in with the new” also applies to the stock market, although the market doesn’t always precisely follow the calendar.Healthcare stocks, which have been superior performers since 2011, lost their mojo this year, and last week they officially suffered a breakdown relative to the market. But as one season turns into the next, new sectors are […]
SummaryThere has definitely been a sector rotation out of biotech stocks and into the consumer goods names that pay high dividend yields.
Amgen remains fairly valued based on 2015 earnings estimates.
The dividend is small but investors received a 29.5% increase to the dividend in the next quarter.
The last time I analyzed Amgen Inc. (NASDAQ:AMGN) on November 25, 2014, I stated, “More […]
Biotech stocks to buy in 2015: Biotech was one of the most profitable sectors this year. Through Dec. 18, the S&P 500 Biotechnology Index is up 43.6% in 2014, and the Nasdaq Biotechnology Index is up 36.9%.Those gains are three to six times as big as the broader markets’. In 2014 through Dec. 18, the Dow Jones Industrial Average is […]
By Ben LevisohnRBC’s Michael Yee and team explain why Celgene (CELG), Biogen Idec (BIIB), Vertex Pharmaceuticals (VRTX), BioMarin Pharmaceutical (BMRN) and Regeneron Pharmaceuticals (REGN) are their top biotech stocks for 2015:
Bloomberg News
Top-five longs: Celgene, Biogen Idec, BioMarin Pharmaceutical, Vertex Pharmaceuticals, Regeneron Pharmaceuticals: 1) Celgene we predict “settlement” with Actavis (ACT) could happen after spring when expert discovery ends and before Court begins mid-15; plus investors should start giving […]
